卡芦莫南与头孢他啶治疗尿路感染的比较。
Carumonam versus ceftazidime for urinary tract infections.
作者信息
Edelstein H, Oster S, Cassano K, McCabe R
机构信息
Section of Infectious Diseases, Veterans Administration Medical Center, Martinez, California 94553.
出版信息
Antimicrob Agents Chemother. 1988 Jul;32(7):1031-3. doi: 10.1128/AAC.32.7.1031.
Carumonam is a new monobactam antibiotic with potent activity against gram-negative aerobes. To study the efficacy and safety of carumonam for treatment of complicated and uncomplicated urinary tract infections, 54 patients were randomized to therapy with either carumonam or ceftazidime. Of 42 patients who could be evaluated, 82% of the carumonam-treated patients and 80% of the ceftazidime-treated patients were cured clinically. At 5 to 9 days posttherapy, microbiologic criteria indicated that 13 carumonam-treated patients (48%) and 8 ceftazidime-treated patients (53%) were cured. Patients with indwelling bladder catheters at the end of therapy had a markedly worse microbiologic outcome than those without catheters. Enterococcus sp. reinfection was common in both groups. Possible adverse clinical and laboratory reactions occurred in six carumonam-treated patients (21%) and four ceftazidime-treated patients (27%). Most reactions occurred at the end of therapy and resolved with discontinuation of the study drug. In this small study, carumonam appeared as safe and as effective as ceftazidime for the treatment of complicated and uncomplicated urinary tract infections.
卡芦莫南是一种新型单环β-内酰胺类抗生素，对革兰氏阴性需氧菌具有强大活性。为研究卡芦莫南治疗复杂性和非复杂性尿路感染的疗效及安全性，将54例患者随机分为卡芦莫南治疗组或头孢他啶治疗组。在42例可评估的患者中，卡芦莫南治疗组82%的患者和头孢他啶治疗组80%的患者临床治愈。治疗后5至9天，微生物学标准显示卡芦莫南治疗组13例患者（48%）和头孢他啶治疗组8例患者（53%）治愈。治疗结束时留置膀胱导管的患者微生物学结果明显比未留置导管的患者差。两组中肠球菌属再感染均很常见。卡芦莫南治疗组6例患者（21%）和头孢他啶治疗组4例患者（27%）出现了可能的不良临床和实验室反应。大多数反应发生在治疗结束时，停用研究药物后症状缓解。在这项小型研究中，卡芦莫南在治疗复杂性和非复杂性尿路感染方面似乎与头孢他啶一样安全有效。
Zotero 插件